Literature DB >> 20400729

Prevalence of antibodies associated with herd immunity: a new indicator to evaluate the establishment of herd immunity and to decide immunization strategies.

Pedro Plans1.   

Abstract

OBJECTIVE: To develop a method to estimate the critical prevalence of antibodies associated with herd immunity (p(c)) and to assess the establishment of herd immunity against measles, mumps, rubella, varicella, and pertussis in Catalonia (Spain) using this method.
METHODS: The herd immunity is established when the prevalence of antibodies (positive serological results) is higher than p(c) = I(c) Se/PV, where I(c) is the prevalence of protected individuals necessary to block the transmission of an infection in the population, Se is the sensitivity of the serological test, and PV is the predictive value of a positive serological result. The establishment of herd immunity was assessed comparing the age-group specific p(c) with the prevalence of antibodies (p) observed in Catalonia in 2002 in schoolchildren (6-9 years) and individuals aged 14 to 29 years and 45 to 54 years.
RESULTS: The herd immunity was not established (p < p(c)) against measles, mumps, and varicella in schoolchildren aged 6 to 9 years, against measles in individuals aged 15 to 24 years, and against pertussis in all age groups. Based on these results, the measles-mumps-rubella (MMR) vaccine should be given to schoolchildren and individuals aged 15 to 24 years, the varicella vaccine to schoolchildren aged 6 to 9 years, and the diphtheria-tetanus-pertussis (DTaP/dTaP) vaccine to all age groups in order to establish the necessary herd immunity in the population.
CONCLUSION: Serological surveys and the critical prevalence of antibodies can be used to assess the establishment of herd immunity for vaccine-preventable diseases in different population groups, indicating to which of them immunization activities should be prioritized.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20400729     DOI: 10.1177/0272989X09353453

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  8 in total

1.  New preventive strategy to eliminate measles, mumps and rubella from Europe based on the serological assessment of herd immunity levels in the population.

Authors:  P Plans
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-16       Impact factor: 3.267

2.  Effectiveness of acellular pertussis vaccination during childhood (<7 years of age) for preventing pertussis in household contacts 1-9 years old in Catalonia and Navarra (Spain).

Authors:  P Plans; D Toledo; M R Sala; N Camps; M Villanova; R Rodríguez; J Alvarez; R Solano; M García-Cenoz; I Barrabeig; P Godoy; S Minguell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-09       Impact factor: 3.267

3.  Prevalence of protective measles virus antibody levels in umbilical cord blood samples in Catalonia, Spain.

Authors:  Pedro Plans; Josep Costa; Angela Domínguez; Núria Torner; Eva Borras; Antoni Plasència
Journal:  Clin Vaccine Immunol       Date:  2010-02-17

4.  Why does measles persist in Europe?

Authors:  P Plans-Rubió
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-05-26       Impact factor: 5.103

5.  Assessing the Effectiveness and Cost-Benefit of Test-and-Vaccinate Policy for Supplementary Vaccination against Rubella with Limited Doses.

Authors:  Masaya M Saito; Keisuke Ejima; Ryo Kinoshita; Hiroshi Nishiura
Journal:  Int J Environ Res Public Health       Date:  2018-03-22       Impact factor: 3.390

6.  Seroprevalence of diphtheria and measles antibodies and their association with demographics, self-reported immunity, and immunogenetic factors in healthcare workers in Latvia.

Authors:  Aija Leidere-Reine; Oksana Kolesova; Aleksandrs Kolesovs; Ludmila Viksna
Journal:  Vaccine X       Date:  2022-02-19

7.  Serological assessment of the establishment of herd immunity against measles in a health district in Malaysia.

Authors:  Y Hazlina; M A Marlindawati; K Shamsuddin
Journal:  BMC Infect Dis       Date:  2016-12-08       Impact factor: 3.090

8.  Vaccination Coverage for Routine Vaccines and Herd Immunity Levels against Measles and Pertussis in the World in 2019.

Authors:  Pedro Plans-Rubió
Journal:  Vaccines (Basel)       Date:  2021-03-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.